The 1st UPGx Personalized Medicine Public Day will be organised in London, UK on Wednesday December 6th, 2017 (18:30-21:00 pm) at the Royal Society.

One of the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalising drug use.

Recognising this fact, the Golden Helix Foundation organizes in London the 1st UPGx Personalized Medicine Public Day. The theme of the meeting will be "Is Personalised Medicine available for all citizens?" and will be organized in the Royal Society in the afternoon of December 6th, 2017 (18:30 - 21:00 p.m.) and is part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (UPGx) project, funded by the European Commission (H2020-668353).

This event is meant for the general public, patient organisations, regulators, insurers and policy makers. Registration is FREE-OF-CHARGE. During the event, drinks and food will be served for free.

To register for this meeting, please click here.

We look forward to welcoming you to London in December.

It is with great pleasure to announce that Dr. Catalina Lopez-Correa has joined the International Scientific Advisory Council of the Golden Helix Foundation.

The 3rd Global Genomic Medicine Collaborative conference was successfully organized in Athens, Greece, April 27th to 29th, 2017. This meeting was the consecutive conference of the previous two, organized in Washington DC (8-9 January 2014) and Singapore (6-8 November 2015).

The 1st UPGx Personalized Medicine Day, the first of a series of dissemination events for healthcare professionals and biomedical scientists that will be organized by the Golden Helix Foundation, in its function as the lead dissemination partner of the UPGx project, has been successfully held on Thursday December 1st, 2016 in Granada, Spain. The theme of the event, that was hosted at the newly built Salón de actos of the Hospital Campus de la Salud, was “Pharmacogenomics for the treatment of cardiovascular diseases”.

The 2016 Golden Helix Summer School with the theme “Cancer Genomics and individualized treatment” was successfully organized in Syros island, Greece, 22-26 September 2016. The conference was attended by approximately 100 participants and speakers from over 20 countries from Europe, Latin America, Middle East, Asia and the United States. The event featured high level scientific lectures, workshops and a career development session, in addition to short presentations by junior researchers and graduate students, who presented their abstracts, which were published in a Supplemental issue of Public Health Genomics, the official journal of the Genomic Medicine Alliance. The lectures in the scientific program were distributed in 5 sessions, related to genome discovery in cancer, pharmacogenomics in cancer treatment, adjacent technologies in cancer genomics, and economic evaluation in cancer genomics. The keynote lecture was delivered by Professor Magnus Ingelman-Sundberg (Karolinska Institutet, Sweden). Most importantly, the inclusion of the general public information session, specifically aiming to raise awareness of the general public regarding the most recent developments in cancer treatment and prevention, was a distinct plus. The social activities contributed towards creating a relaxing environment among participants and speakers that was conductive to establishing new or strengthening existing collaborations and/or opened up training opportunities.

The Golden Helix Foundation has agreed to co-organize, together with the Global Genomic Medicine Collaborative (G2MC) its 3rd annual meeting in Athens, Greece April 27-29, 2017. The conference will have the format of a Golden Helix Symposium and the tentative theme will be “Implementing Genomics into the clinic”.

Registration fees will be waived for all participants, while a handful of registration slots will be made available for graduate and undergraduate students interested in the field of genomic medicine.